BR9709066A - Estìmulo de mecanismos de defesa de hospedeiro contra desafios virais. - Google Patents

Estìmulo de mecanismos de defesa de hospedeiro contra desafios virais.

Info

Publication number
BR9709066A
BR9709066A BR9709066-2A BR9709066A BR9709066A BR 9709066 A BR9709066 A BR 9709066A BR 9709066 A BR9709066 A BR 9709066A BR 9709066 A BR9709066 A BR 9709066A
Authority
BR
Brazil
Prior art keywords
defense mechanisms
against viral
host defense
mechanisms against
stimulating
Prior art date
Application number
BR9709066-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Michael Gerard Tovey
Original Assignee
Pharma Pacific Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Pacific Pty Ltd filed Critical Pharma Pacific Pty Ltd
Publication of BR9709066A publication Critical patent/BR9709066A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
BR9709066-2A 1996-05-09 1997-05-05 Estìmulo de mecanismos de defesa de hospedeiro contra desafios virais. BR9709066A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPN9765A AUPN976596A0 (en) 1996-05-09 1996-05-09 Stimulation of host defence mechanisms
PCT/IB1997/000489 WO1997041883A1 (en) 1996-05-09 1997-05-05 Stimulation of host defense mechanisms against viral challenges

Publications (1)

Publication Number Publication Date
BR9709066A true BR9709066A (pt) 2000-01-04

Family

ID=3794078

Family Applications (2)

Application Number Title Priority Date Filing Date
BR9709066-2A BR9709066A (pt) 1996-05-09 1997-05-05 Estìmulo de mecanismos de defesa de hospedeiro contra desafios virais.
BR9709223-1A BR9709223A (pt) 1996-05-09 1997-05-05 Estimulação dos mecanismos de defesa do hospedeiro contra tumores.

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR9709223-1A BR9709223A (pt) 1996-05-09 1997-05-05 Estimulação dos mecanismos de defesa do hospedeiro contra tumores.

Country Status (17)

Country Link
EP (2) EP0898478B1 (enExample)
JP (2) JP3806446B2 (enExample)
KR (2) KR100399501B1 (enExample)
CN (1) CN1154508C (enExample)
AR (2) AR007058A1 (enExample)
AT (2) ATE316791T1 (enExample)
AU (3) AUPN976596A0 (enExample)
BR (2) BR9709066A (enExample)
CA (2) CA2253908A1 (enExample)
DE (2) DE69735204T2 (enExample)
ES (2) ES2260794T3 (enExample)
ID (2) ID16886A (enExample)
IL (2) IL126972A0 (enExample)
NZ (2) NZ332690A (enExample)
TW (1) TW528599B (enExample)
WO (2) WO1997041886A1 (enExample)
ZA (1) ZA973988B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6299871B1 (en) * 1998-07-24 2001-10-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Orally-administrable therapeutic and/or prophylactic agent for HTLV-1-related diseases
EP1180037A2 (en) * 1999-05-26 2002-02-20 The Brigham and Women's Hospital Therapeutic uses of agents that modulate the activity of alpha-smooth muscle actin
US6710025B1 (en) 1999-05-26 2004-03-23 The Brigham And Women's Hospital, Inc. Treatment of damaged tissue using agents that modulate the activity of alpha-smooth muscle actin
US20040258663A1 (en) * 2003-05-08 2004-12-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon alpha
ES2294589T3 (es) 2004-04-29 2008-04-01 F. Hoffmann-La Roche Ag Variacion de la secuencia nucleosida de ns5a como marcador.
DE102007014752A1 (de) 2007-03-28 2008-10-02 Dusek, Niels, Dr. Verwendung von humanidentischem oder humanaequivalentem rekombinantem Interleukin-2 (heqlL-2) als Therapeutikum in der Human- und Veterinärmedizin

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1982000588A1 (en) * 1980-08-22 1982-03-04 Illinois Univ Delivery of biologically active components of heterologous species interferon isolates
US5286748A (en) * 1981-01-05 1994-02-15 Eby Iii George A General method of shortening the duration of common colds by application of medicaments to tissues of oral cavity
US4820515A (en) * 1982-12-13 1989-04-11 Texas A&M University System Method of using interferon in low dosage to regulate appetite and efficiency of food utilization
US4605555A (en) * 1984-09-20 1986-08-12 Sun Star Kabushiki Kaisha Composition and method for treating keratosic disorder of skin and mucosa
IL76591A0 (en) * 1984-10-05 1986-02-28 Bioferon Biochem Substanz Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof
ZA878295B (en) * 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
JP2704546B2 (ja) * 1989-04-04 1998-01-26 光利 太良 Ａｔｌｌ治療用吸入剤
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5215741A (en) * 1990-10-30 1993-06-01 Amarillo Cell Culture Company, Incorporated Method for prevention of parasite infections
JPH06503570A (ja) * 1990-12-14 1994-04-21 シェリング・コーポレーション 肺の悪性腫瘍類を治療するためのアルファーインターフェロンの経口投与
US5780021A (en) * 1993-03-05 1998-07-14 Georgetown University Method for treating type 1 diabetes using α-interferon and/or β-i
IL113280A (en) * 1994-04-12 2004-12-15 Res Dev Foundation A preparation for the treatment of self-immunization diseases with the help of interferon of one type
CN1151841C (zh) * 1996-05-09 2004-06-02 太平洋制药控股公司 干扰素在制备刺激防御机制或免疫反应的药物中的应用

Also Published As

Publication number Publication date
EP0898478A1 (en) 1999-03-03
KR100399501B1 (ko) 2003-12-18
TW528599B (en) 2003-04-21
DE69735201D1 (de) 2006-04-13
NZ332688A (en) 2000-07-28
AU2710997A (en) 1997-11-26
KR100399499B1 (ko) 2003-12-18
CA2253908A1 (en) 1997-11-13
ATE316791T1 (de) 2006-02-15
NZ332690A (en) 2000-07-28
DE69735204D1 (de) 2006-04-13
KR20000010882A (ko) 2000-02-25
AR007059A1 (es) 1999-10-13
BR9709223A (pt) 2000-12-12
EP0956040B1 (en) 2006-02-01
ATE316793T1 (de) 2006-02-15
WO1997041886A1 (en) 1997-11-13
JP2000504027A (ja) 2000-04-04
CN1218409A (zh) 1999-06-02
ID16886A (id) 1997-11-20
DE69735201T2 (de) 2006-09-21
AR007058A1 (es) 1999-10-13
EP0956040A4 (enExample) 1999-11-17
CA2253902A1 (en) 1997-11-13
ID16885A (id) 1997-11-20
AU2399297A (en) 1997-11-26
ES2260790T3 (es) 2006-11-01
ZA973988B (en) 1998-11-09
JP2000504026A (ja) 2000-04-04
JP3806444B2 (ja) 2006-08-09
IL126972A0 (en) 1999-09-22
IL126970A0 (en) 1999-09-22
AU729514B2 (en) 2001-02-01
DE69735204T2 (de) 2006-09-21
CN1154508C (zh) 2004-06-23
WO1997041883A1 (en) 1997-11-13
EP0956040A1 (en) 1999-11-17
KR20000010880A (ko) 2000-02-25
AUPN976596A0 (en) 1996-05-30
AU724190B2 (en) 2000-09-14
EP0898478A4 (en) 1999-05-26
ES2260794T3 (es) 2006-11-01
JP3806446B2 (ja) 2006-08-09
EP0898478B1 (en) 2006-02-01

Similar Documents

Publication Publication Date Title
ID17768A (id) Metoda pengobatan
BR9807577A (pt) Método para prevenir e retardar o inìcio da doença de alzheimer e sua composição
BR9713792A (pt) Administração de mucosa de substância aos mamìferos
UA27231C2 (uk) Застосування модафінілу як лікувального засобу, що має протиішемічну дію на церебральному рівні
NO931267D0 (no) Fremgangsmaate for behandling eller forebyggelse av type 1diabetes ved oral administrering av insulin
BR9910505A (pt) Terapia de combinação compreendendo ribavirina e interferon alfa em pacientes cândidos de tratamento antiviral tendo infecção crÈnica por hepatite c
BR0007743A (pt) Epa etìlico altamente purificado e outrosderivados de epa para distúrbios psiquiátricos eneurológicos
IL124977A0 (en) Oral administration of effective amounts of forms of hyaluronic acid
IT1252868B (it) Composizione farmaceutica anticefalalgica per somministrazione endonasale, procedimento per prepararla e suo impiego terapeutico
KR970704429A (ko) 심혈관 질환의 치료를 위한 드롤록시펜의 용도(use of droloxifene for the treatment of cardiovascular diseases)
EP0850068A4 (en) LIPID EXTRACTS WITH ANTI-INFLAMMATORY ACTIVITY
BR9811121A (pt) Produto, composição farmacêutica, e uso de um produto
BR9507561A (pt) Ligação de E-selectina P-selectina ou L-selectina para sialil-lewis X ou sialil-lewis A
BR9809425A (pt) Conjugados alfa interferon-polietilenoglicol para terapia de infecção
KR960703009A (ko) 중추유래의 수면성 무호흡증 및 호흡곤란증의 치료를 위한 모다피닐의 사용
BR9809951A (pt) Método para tratamento da obesidade
BR9808875A (pt) Combinação de analgésicos
KR950007848A (ko) (S)-(-)-α-에틸-2-옥소-1-피롤리딘아세트아미드를 사용한 불안치료방법
BR9709066A (pt) Estìmulo de mecanismos de defesa de hospedeiro contra desafios virais.
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
BR0005797A (pt) Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
BR9813549A (pt) Processo para prevenção e tratamento de miocárdio afetado por lesão
BG102342A (en) Optical active derivative of phenylpyrimidine as an anlgesics
DE3875349D1 (de) Glykosaminoglykan zur behandlung von diabetischer mikroangiopathie.
BR0315495A (pt) Composição para reduzir ingestão calórica

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A , 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1855 DE 25/07/2006.